These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9829731

  • 21. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 22. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study.
    Rosen ST, Zimmer AM, Goldman-Leikin R, Gordon LI, Kazikiewicz JM, Kaplan EH, Variakojis D, Marder RJ, Dykewicz MS, Piergies A.
    J Clin Oncol; 1987 Apr; 5(4):562-73. PubMed ID: 3549989
    [Abstract] [Full Text] [Related]

  • 23. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ.
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [Abstract] [Full Text] [Related]

  • 25. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma.
    Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M.
    J Nucl Med; 1987 Mar; 28(3):281-7. PubMed ID: 3102699
    [Abstract] [Full Text] [Related]

  • 26. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients.
    Schroff RW, Farrell MM, Klein RA, Oldham RK, Foon KA.
    J Immunol; 1984 Sep; 133(3):1641-8. PubMed ID: 6379051
    [Abstract] [Full Text] [Related]

  • 27. Prevention of radiolysis of monoclonal antibody during labeling.
    Chakrabarti MC, Le N, Paik CH, De Graff WG, Carrasquillo JA.
    J Nucl Med; 1996 Aug; 37(8):1384-8. PubMed ID: 8708780
    [Abstract] [Full Text] [Related]

  • 28. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL.
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [Abstract] [Full Text] [Related]

  • 29. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
    Yao Z, Garmestani K, Wong KJ, Park LS, Dadachova E, Yordanov A, Waldmann TA, Eckelman WC, Paik CH, Carrasquillo JA.
    J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
    [Abstract] [Full Text] [Related]

  • 30. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
    Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1192-8. PubMed ID: 16965873
    [Abstract] [Full Text] [Related]

  • 31. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
    Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID.
    Cancer Res; 1996 May 01; 56(9):2123-9. PubMed ID: 8616860
    [Abstract] [Full Text] [Related]

  • 32. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM.
    J Nucl Med; 2005 Apr 01; 46(4):620-33. PubMed ID: 15809485
    [Abstract] [Full Text] [Related]

  • 33. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D.
    Clin Cancer Res; 2000 Aug 01; 6(8):3095-102. PubMed ID: 10955789
    [Abstract] [Full Text] [Related]

  • 34. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug 01; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 35. Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
    Pai-Scherf LH, Carrasquillo JA, Paik C, Gansow O, Whatley M, Pearson D, Webber K, Hamilton M, Allegra C, Brechbiel M, Willingham MC, Pastan I.
    Clin Cancer Res; 2000 May 01; 6(5):1720-30. PubMed ID: 10815890
    [Abstract] [Full Text] [Related]

  • 36. Tissue distribution and serum kinetics of T101 monoclonal antibody during passive anti-cancer therapy.
    Shawler DL, Beauregard J, Halpern SE, Baird SM, Dillman RO.
    Clin Immunol Immunopathol; 1986 Oct 01; 41(1):43-54. PubMed ID: 3488861
    [Abstract] [Full Text] [Related]

  • 37. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia.
    Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C, Frankel AE.
    J Biol Response Mod; 1988 Feb 01; 7(1):97-113. PubMed ID: 3373237
    [Abstract] [Full Text] [Related]

  • 38. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
    Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD.
    Cancer Biother Radiopharm; 1999 Apr 01; 14(2):99-111. PubMed ID: 10850293
    [Abstract] [Full Text] [Related]

  • 39. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS, Hird V, Snook D, Sullivan M, Myers MJ, Epenetos AA.
    Int J Cancer Suppl; 1988 Apr 01; 3():71-6. PubMed ID: 3209303
    [Abstract] [Full Text] [Related]

  • 40. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM.
    Cancer; 1999 Oct 01; 86(7):1368-76. PubMed ID: 10506727
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.